Use of administrative claims data in observational studies of antirheumatic medication effects on pregnancy outcomes: a scoping review protocol

被引:1
|
作者
Tharmarajah, Shenthuraan [1 ]
Guilcher, Sara [1 ,2 ]
Santhireswaran, Araniy [1 ]
Mccarthy, Lisa [1 ,2 ,3 ]
Mahendira, Dharini [4 ]
Berger, Howard [5 ]
Tadrous, Mina [1 ,3 ]
机构
[1] Univ Toronto, Leslie Dan Fac Pharm, Toronto, ON, Canada
[2] Trillium Hlth Partners, Inst Better Hlth, Mississauga, ON, Canada
[3] Womens Coll Hosp, Womens Coll Res Inst, Toronto, ON, Canada
[4] Univ Toronto, Dept Med, Div Rheumatol, Toronto, ON, Canada
[5] St Michaels Hosp, Dept Obstet & Gynecol, Toronto, ON, Canada
关键词
drug safety; maternal-fetal medicine; pregnancy; rheumatic diseases; scoping review; GUIDELINE; DISEASES; DRUGS; WOMEN;
D O I
10.11124/JBIES-23-00039
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objective:The primary objective of this review is to examine which disease-modifying antirheumatic drugs (DMARDs) and biologics used to treat pregnant individuals with rheumatic conditions have been reported in observational studies using population-based health administrative data. The secondary objective is to describe which adverse pregnancy outcomes (both maternal and neonatal) have been reported, their definitions, and corresponding diagnostic and/or procedural codes.Introduction:Pregnant individuals are typically excluded from drug trials due to unknown potential risks to both the pregnant person and fetus, leaving most antirheumatic drugs understudied for use in pregnancy. Despite these substantial knowledge gaps, most pregnant individuals continue to be maintained on antirheumatic medications due to the benefits generally outweighing the risks. In contrast to previous systematic reviews of findings from randomized trials, our scoping review aims to leverage this real-world data to generate real-world evidence of antirheumatic drug safety during pregnancy.Inclusion criteria:Articles must report on observational studies using population-based health administrative data from pregnant individuals with rheumatic conditions (rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis, and psoriatic arthritis) receiving antirheumatic drug therapy (DMARDs and biologics). Randomized trials, reviews, case studies, opinion pieces, and abstracts will be excluded.Methods:Electronic databases (MEDLINE [Ovid], Embase [Ovid], CINAHL [EBSCOhost]) and gray literature (OpenGrey, Health Services Research Projects in Progress, World Health Organization Library, and Google Scholar) will be searched for relevant evidence. Search terms will combine 4 concepts: rheumatic diseases, drug therapy, pregnancy, and health care administrative data. Identified articles will be independently screened, selected, and extracted by 2 researchers. Data will be analyzed descriptively and presented in tables.Review registration:Open Science Framework https://osf.io/5e6tp
引用
收藏
页码:106 / 115
页数:10
相关论文
共 50 条
  • [41] Leveraging Administrative Data to Better Understand and Address Child Maltreatment: A Scoping Review of Data Linkage Studies
    Soneson, Emma
    Das, Shruti
    Burn, Anne-Marie
    van Melle, Marije
    Anderson, Joanna K.
    Fazel, Mina
    Fonagy, Peter
    Ford, Tamsin
    Gilbert, Ruth
    Harron, Katie
    Howarth, Emma
    Humphrey, Ayla
    Jones, Peter B.
    Moore, Anna
    CHILD MALTREATMENT, 2023, 28 (01) : 176 - 195
  • [42] Fracture outcome coding in observational osteoporosis drug effects studies: A scoping review
    Konstantelos, Natalia
    Rzepka, Anna M.
    Burden, Andrea M.
    Cheung, Angela M.
    Kim, Sandra
    Grootendorst, Paul
    Cadarette, Suzanne M.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 232 - 232
  • [43] Intrahepatic cholestasis of pregnancy and gestational diabetes: Protocol for a scoping review of associations, risk factors, and outcomes
    Abubakr, Karima
    Kennedy, Clare
    Al-Tikriti, Shahad
    O'Higgins, Amy C.
    Coveney, Ciara
    Hatunic, Mensud
    Higgins, Mary F.
    Sergi, Consolato
    Sergi, Consolato
    PLOS ONE, 2025, 20 (03):
  • [44] Effects of Cannabis Use on Neurocognition: A Scoping Review of MRI Studies
    Audi, Dima
    Hajeer, Shorouk
    Saab, Marie-Belle
    Saab, Lea
    Harati, Hayat
    Desoutter, Alban
    Al Ahmar, Elie
    Estephan, Elias
    JOURNAL OF PSYCHOACTIVE DRUGS, 2024,
  • [45] Mapping outcomes for recovery of consciousness in studies from 1986 to 2020: a scoping review protocol
    Weaver, Jennifer
    Cogan, Alison
    Bhandari, Parie
    Zainab, Bint-e Awan
    Jacobs, Erica
    Pape, Ariana
    Nguyen, Chantal
    Guernon, Ann
    Harrod, Tom
    Pape, Theresa Bender
    Mallinson, Trudy
    BMJ OPEN, 2022, 12 (06):
  • [46] Research outcomes of linked prescription drug monitoring program data: a scoping review protocol
    Cummins, Mollie
    Turcotte, Catherine
    McFarland, Mary M.
    Staes, Catherine
    BMJ OPEN, 2022, 12 (04):
  • [47] MAPPING THE USE OF GROUP-BASED TRAJECTORY MODELLING IN MEDICATION ADHERENCE RESEARCH: A SCOPING REVIEW PROTOCOL
    Walsh, C.
    Mucherino, S.
    Orlando, V
    Bennett, K. E.
    Menditto, E.
    Cahir, C.
    VALUE IN HEALTH, 2020, 23 : S618 - S618
  • [48] The Volume and Tone of Twitter Posts About Cannabis Use During Pregnancy: Protocol for a Scoping Review
    Cresswell, Liam
    Espin-Noboa, Lisette
    Murphy, Malia S. Q.
    Ramlawi, Serine
    Walker, Mark C.
    Karsai, Marton
    Corsi, Daniel J.
    JMIR RESEARCH PROTOCOLS, 2022, 11 (03):
  • [49] Discrepancies Identified with the Use of Prescription Claims and Diagnostic Billing Data Following a Comprehensive Medication Review
    Roane, Teresa E.
    Patel, Vinita
    Hardin, Heather
    Knoblich, Martha
    JOURNAL OF MANAGED CARE PHARMACY, 2014, 20 (02): : 165 - 173
  • [50] SYSTEMATIC REVIEW OF VALIDATION STUDIES TO IDENTIFY LIVER, LUNG, BRAIN AND BONE METASTASES IN ADMINISTRATIVE CLAIMS DATA
    Hincapie, A. L.
    Saverno, K. R.
    Carter, Cuyun G.
    Costa, L.
    Hughes, V
    Starbuck, E.
    Heaton, P. C.
    VALUE IN HEALTH, 2019, 22 : S103 - S104